- Global Pharma News & Resources

Creative Diagnostics Introduces New SARS-CoV-2 Neutralizing Antibody ELISA Kit

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics released two ELISA kits for qualitative detection of SARS-CoV-2 neutralizing antibody in serum and plasma to meet the demand of customers for vaccine development. The new series of SARS-CoV-2 Neutralizing Antibody ELISA Kit include the SARS-CoV-2 Neutralizing Antibody Assay Kit(DEIASL055) and SARS-CoV-2 Neutralizing Antibody Assay Kit(DEIA-WZ021), which are used for evaluating immune responses to COVID-19, and have applications in studies of human immunity and vaccine development.

SARS-CoV-2 Neutralizing Antibody Assay Kit (DEIASL055), the RBD Neutralizing Antibody competitive ELISA Kit, is an enzyme-linked immunosorbent assay intended for the qualitative detection of RBD neutralizing antibodies in serum or plasma. S protein contains a receptor-binding domain(RBD) which is one of the vital immunodominant epitopes and has a superior capacity to induce neutralizing antibodies. It is proved that RBD is responsible for recognizing and interacting with the cell surface receptor, angiotensin-converting enzyme-2 (ACE2). For DEIASL055, recombinant human ACE2 receptor protein is immobilized on the plate, followed by the addition of neutralizing antibody or HRP labelled RBD. This interaction is then detected by reading absorbance at 450 nm. The interaction between SARS-CoV-2 spike RBD and ACE2 is disrupted in the presence of neutralizing antibodies in the sample, preventing signal emission

Another product is the SARS-CoV-2 Neutralizing Antibody ELISA Kit (DEIA-WZ021), which is used for the qualitative determination of SARS-CoV-2 neutralizing antibody concentrations in serum and plasma. For DEIA-WZ021, recombinant RBD protein is immobilized on the plate instead of human ACE2 and HRP labelled recombinant human ACE2 is added into the plate to compete with neutralizing antibody. This assay format allows for the detection of all neutralizing antibodies independent of isotype, including IgA, which is particularly salient to mucosal tissue infections.

"The detection of neutralizing antibodies can provide valuable information for researchers studying immune responses or human immunity to SARS-CoV-2, as well as for the development of effective vaccines. In addition to our SARS-CoV-2 Neutralizing Antibodies, we continuously expand our product portfolio and now offer SARS-CoV-2 Neutralizing Antibody ELISA Kits for researchers to combat the COVID-19 pandemic." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

"Our SARS-CoV-2 Neutralizing Antibody ELISA Kits function as a simple, qualitative, and convenient indicator of positive or negative samples. The entire detection process takes about 80 minutes, while traditional neutralization experiments require cell culture, which usually takes 2-3 days to complete the test. The format of our ELISA also provides an efficient and effective screening tool for determining functional antibody neutralization capabilities. In addition, we also offer Antigens and Antibodies for COVID-19 Neutralizing Antibody Assays, such as the Recombinant Human ACE2, Recombinant SARS-CoV-2 Spike Protein, and Humanized SARS-CoV-2 Neutralizing Antibody for scientists." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about our SARS-CoV-2 related ELISA Kits, antibodies or other research materials, please visit Creative Diagnostics at

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

Editor Details

Last Updated: 21-Apr-2021